The growing A-fib market continues to gain the attention of the major players this week: GE Ventures helped Acutus Medical to close a $28 million Series B round. The San Diego-based startup is working to develop a minimally invasive, real-time 3-D Cardiac Chamber Imaging and Dipole Density Mapping system. This technology could help physicians locate the actual location of the problems for atrial fibrillation, among other kinds of complex cardiac arrhythmias.
Two-year old Acutus had raised $21 million by the end of June without GE. Other investors include: Orbimed, as well as Acutus’s existing investors, Advent Ventures and Index Ventures.
The money will go to product development, clinical trials, regulatory approvals and early commercialization, according to a company statement.
Why Pharma Companies Should Look To Social Media For Better Patient Insight
Healthcare decision-makers, especially at pharmaceutical companies, must prioritize patient input. Data collected from social media listening is a significant step in the right direction.
Acutus CEO Randy Werneth said in a statement that the information this device gives should allow physicians to offer precise treatment and monitor therapy progress more efficiently.